Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Evommune presented late-breaking Phase 2a proof-of-concept data for EVO301 in moderate-to-severe atopic dermatitis at the EADV 2026 Congress, meeting the primary endpoint with a 55% LS-mean EASI reduction at Week 12 versus 22% on placebo (p<0.01). Responses deepened over time despite only two IV doses, with EASI-75 of 29% vs 9% placebo at Week 12 and a placebo-like safety profile including no conjunctivitis.
Key figures
- Drug Name
- EVO301
- Phase Of Trial
- Phase 2a
- Easi50 week12
- 63% vs 23% placebo
- Easi75 week12
- 29% vs 9% placebo
- Phase2b start
- mid-2027
- Trial patients
- 70
- Active patients
- 48
- Placebo patients
- 22
- Treatment related aes
- 10.4% active vs 13.6% placebo
- Easi reduction week12 active
- 55%
- Easi reduction week12 placebo
- 22%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.